Literature DB >> 11728162

Prostaglandin E(2) modulation of vascular endothelial growth factor production in murine macrophages.

M Mukutmoni1, N E Hubbard, K L Erickson.   

Abstract

We have previously shown that dietary (n-3) fatty acids decrease mammary tumor vascularization and PGE(2) production. One possible mechanism may be the modulation of vascular endothelial growth factor (VEGF) production by PGE(2). Macrophages are major producers of VEGF, and thus we assessed the role of PGE(2) in vitro and in vivo on their VEGF production. When added to macrophages, pharmacological (10(-7) M) but not physiological (10(-9) to 10(-11) M) concentrations of PGE(2) increased VEGF mRNA and protein levels. That increased expression was relatively rapid and sustained up to 8 hrs, but declined by 24 hrs. Similarly, dibutryl cAMP increased production of VEGF protein which was completely inhibited by H89. Addition of cAMP-elevating agents further potentiated the production of VEGF by PGE(2). Next, (n-3) and (n-6) fatty acids were added to macrophages in vitro or provided in the diet. Macrophages of mice fed safflower oil (n-6) had 2- to 4-fold greater copy number of VEGF transcripts after lipopolysaccarhide (LPS) stimulation compared to fish oil (n-3). A decreasing trend was seen in LPS-induced VEGF secretion from macrophages in vitro after docosahexaenoic acid or eicosapentaenoic acid incubation compared to arachidonic acid. While pharmacological concentrations of PGE(2) modulate VEGF expression, physiological alterations did not alter VEGF protein production by macrophages. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11728162     DOI: 10.1054/plef.2001.0300

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  7 in total

Review 1.  The role of antioxidants in models of inflammation: emphasis on L-arginine and arachidonic acid metabolism.

Authors:  M Kapoor; A N Clarkson; B A Sutherland; I Appleton
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

2.  MK886 inhibits the proliferation of HL-60 leukemia cells by suppressing the expression of mPGES-1 and reducing prostaglandin E2 synthesis.

Authors:  YiQing Li; SongMei Yin; DaNian Nie; ShuangFeng Xie; LiPing Ma; XiuJu Wang; YuDan Wu; Jie Xiao
Journal:  Int J Hematol       Date:  2011-10-29       Impact factor: 2.490

3.  The inhibition of lung colonization of B16-F10 melanoma cells in EFA-deficient animals is related to enhanced apoptosis and reduced angiogenesis.

Authors:  Antonella Mannini; Anna Calzolari; Lido Calorini; Gabriele Mugnai; Salvatore Ruggieri
Journal:  Clin Exp Metastasis       Date:  2006-09-22       Impact factor: 5.150

4.  Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor.

Authors:  Li Yang; Noboru Yamagata; Rajwardhan Yadav; Suzanne Brandon; Regina L Courtney; Jason D Morrow; Yu Shyr; Mark Boothby; Sebastian Joyce; David P Carbone; Richard M Breyer
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

5.  COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables.

Authors:  G Perrone; D Santini; A Verzì; B Vincenzi; D Borzomati; F Vecchio; R Coppola; A Antinori; P Magistrelli; G Tonini; C Rabitti
Journal:  J Clin Pathol       Date:  2006-02-17       Impact factor: 3.411

6.  Novel mechanisms and signaling pathways of esophageal ulcer healing: the role of prostaglandin EP2 receptors, cAMP, and pCREB.

Authors:  Amrita Ahluwalia; Dolgor Baatar; Michael K Jones; Andrzej S Tarnawski
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-07-24       Impact factor: 4.052

7.  Induction of a potential paracrine angiogenic loop between human THP-1 macrophages and human microvascular endothelial cells during Bartonella henselae infection.

Authors:  Sandra I Resto-Ruiz; Michael Schmiederer; Debra Sweger; Catherine Newton; Thomas W Klein; Herman Friedman; Burt E Anderson
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.